{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117199","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.309660+00:00","generated_at":"2026-06-08T04:37:42.822543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyclacel reports Q3 net loss of $6.1M; cash runway only through end of 2023","bullets":["Cash equivalents $5.9M at Sep 30, 2023, down from $18.3M at Dec 31, 2022.","Net loss of $6.1M for Q3 2023 vs $5.1M in Q3 2022; R&D spend rose to $5.2M.","Available cash funds planned programs only through end of 2023; discretionary cuts could extend into Q2 2024.","Fadraciclib dose escalation near RP2D selection; plogosertib recruiting at dose level 5 with epigenetic mechanism under study.","UK R&D tax credits reduced to $0.6M in Q3 2023 from $1.0M due to legislative changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117199","json":"https://secwatch.observer/filing/0001104659-23-117199.json","markdown":"https://secwatch.observer/filing/0001104659-23-117199.md","text":"https://secwatch.observer/filing/0001104659-23-117199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/0001104659-23-117199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/tm2330442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:37:42.822543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17931a1fcdc5d21096b977c3c0a7ca91a32076ed","claim":"Bio Green Med Solution, Inc. reported third quarter ended September 30, 2023 results: net income $6.1 million.","evidence_excerpt":"Net loss for the three months ended September 30, 2023, was $6.1 million, compared to $5.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/0001104659-23-117199-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$6.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}